Volume : 10, Issue : 12, December – 2023
Title:
DYSLIPIDEMIA CONSEQUENCES AND MANAGEMENT
Authors :
Fatmah Saeed Baqar, Amjed Abdulameer Hussein Alhilfi, Atif Mohammed Hakami, Hamad Abdulrahman Algaeed, Nabeel Jaber Alharbi, Deena Abdullah Al Saglab, Wael Elsaid Khedr, Saad M. Alqahtani, Wafa Abdullah Alshamrani, Zahrh Husain Alkhalifah, Egbal Lateef Mefleh Al-Fadhli, Mased Ayedh Almutairi, Hussain Marzooq Lasloom, Mohammed Saeed Alnefaie
Abstract :
Background: The pathophysiology of dyslipidemia involves genetic predispositions, dietary factors, insulin resistance, hepatic lipid metabolism, inflammation, hormonal influences, and medications. Genetic variations affecting lipid metabolism and lifestyle factors, such as an unhealthy diet and insulin resistance, contribute to the accumulation of atherogenic biomolecules and the development of atherosclerosis. Furthermore, hormonal imbalances, as seen in thyroid disorders and hormonal medications, can disrupt lipid homeostasis.
Objective: This review will review the most recent medical literature on the consequences and management of dyslipidemia.
Methodology: Comprehensive research on the consequences and management of dyslipidemia. PUBMED and Google Scholar search engines were the databases used for the search process, and articles were collected from 1980 to 2023.
Conclusion: dyslipidemia, characterized by abnormal lipid levels in the blood, poses a significant risk for cardiovascular disease (CVD) and other health complications. The interplay of genetic, environmental, and hormonal factors contributes to disruptions in lipid metabolism, leading to elevated levels of cholesterol and triglycerides. This dysregulation is associated with severe consequences, including atherosclerosis, coronary heart disease, ischemic stroke, pancreatitis, and nonalcoholic fatty liver disease. understanding the complex interplay of factors contributing to dyslipidemia is essential for effectively managing and preventing associated health risks. A comprehensive approach that addresses lifestyle factors and utilizes appropriate pharmacotherapy can significantly reduce the burden of dyslipidemia-related complications, promoting cardiovascular health and overall well-being.
Keywords: dyslipidemia, etiology, pathophysiology, consequences, and management
Cite This Article:
PPlease cite this article in press Fatmah Saeed Baqar et al., Dyslipidemia Consequences And Management, Indo Am. J. P. Sci, 2023; 10 (12).
Number of Downloads : 10
References:
1. Eliche Mozas P, Cruz Romero L, Cubillas Quero A, Huertas Escribano MJ, Rus Mansilla C, Cortez Quiroga GA: Consequences of diabetes and high-risk dyslipidemia. European Journal of Preventive Cardiology. 2023, 30. 10.1093/eurjpc/zwad125.161
2. Thompson GR: Clinical consequences of hyperlipidaemia. J Inherit Metab Dis. 1988, 11 Suppl 1:18-28. 10.1007/bf01800567
3. O’Hagan R, Berg AR, Hong CG, Parel PM, Mehta NN, Teague HL: Systemic consequences of abnormal cholesterol handling: Interdependent pathways of inflammation and dyslipidemia. Frontiers in Immunology. 2022, 13. 10.3389/fimmu.2022.972140
4. Kavey R-EW, Mietus-Snyder M: Beyond Cholesterol: The Atherogenic Consequences of Combined Dyslipidemia. The Journal of Pediatrics. 2012, 161:977-979. 10.1016/j.jpeds.2012.07.034
5. Arvanitis M, Lowenstein CJ: Dyslipidemia. Annals of Internal Medicine. 2023, 176:ITC81-ITC96. 10.7326/AITC202306200
6. Dyslipidemia. Prevention and Management of Cardiovascular and Metabolic Disease. 2023. 259-274. https://doi.org/10.1002/9781119833475.ch17
7. Merlo G, Berra K: Lifestyle Nursing. CRC Press. 2022. https://doi.org/10.1201/9781003178330
8. Bethell HJN, Brodie D: Exercise: A Scientific and Clinical Overview. CABIdigitallibrary. 2023. https://doi.org/10.1079/9781800621855.0012
9. Simha V: Drug-Induced Dyslipidemia. Dyslipidemias: Pathophysiology, Evaluation and Management. Garg A (ed): Humana Press, Totowa, NJ; 2015. 267-286. 10.1007/978-1-60761-424-1_15
10. Purva A, Sharma K, Khan MS: A Review on Dyslipidemia: Types, Risk Factors and Management. Asian Journal of Pharmaceutical Research and Development. 2020, 8:96-98. 10.22270/ajprd.v8i2.682
11. Jin J: Lipid Disorders: Screening and Treatment. JAMA. 2016, 316:2056. 10.1001/jama.2016.16650
12. Reiber I, Mezo I, Mark L, Paragh G: The Good, the Bad, and the Atherogenic. Journal of the American College of Cardiology. 2012, 59:1333-1334. https://doi.org/10.1016/j.jacc.2011.09.058
13. Adnan T, Ahmad M, Chaudhri W, et al.: Pathophysiology of Dyslipidemia and its Management by PCSK9 Inhibitors: A Literature Review. Internal Medicine and Medical Investigation Journal. 2018.
14. Goldstein JL, Brown MS: The Cholesterol Quartet. Science. 2001, 292:1310-1312. 10.1126/science.1061815
15. Reaven GM: Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am. 2011, 95:875-892. 10.1016/j.mcna.2011.06.002
16. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation. 2002, 109:1125-1131. 10.1172/jci15593
17. Libby P, Ridker PM, Hansson GK: Progress and challenges in translating the biology of atherosclerosis. Nature. 2011, 473:317-325. 10.1038/nature10146
18. Duntas LH, Brenta G: A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism. Front Endocrinol (Lausanne). 2018, 9:511. 10.3389/fendo.2018.00511
19. Pivonello R, De Leo M, Vitale P, et al.: Pathophysiology of Diabetes Mellitus in Cushing’s Syndrome. Neuroendocrinology. 2010, 92:77-81. 10.1159/000314319
20. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR: Menopause and risk factors for coronary heart disease. N Engl J Med. 1989, 321:641-646. 10.1056/nejm198909073211004
21. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL: Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002, 25:55-60. 10.2337/diacare.25.1.55
22. Wei L, MacDonald TM, Walker BR: Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004, 141:764-770. 10.7326/0003-4819-141-10-200411160-00007
23. Després J-P, Lemieux I: Abdominal obesity and metabolic syndrome. Nature. 2006, 444:881-887. 10.1038/nature05488
24. Liu H, Peng D: Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. Endocrine Connections. 2022, 11:e210002. 10.1530/EC-21-0002
25. Sarva RP, Gavaler JS, Van Thiel DH: Thiazide-induced hypercholesterolemia: Sex differences. Life Sciences. 1985, 37:1817-1822. https://doi.org/10.1016/0024-3205(85)90224-3
26. Davidson MH: Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia. eBioMedicine. 2015, 2:284. 10.1016/j.ebiom.2015.03.004
27. Deedwania P: Hypertension, Dyslipidemia, and Insulin Resistance in Patients With Diabetes Mellitus or the Cardiometabolic Syndrome: Benefits of Vasodilating β-Blockers. The Journal of Clinical Hypertension. 2011, 13:52-59. https://doi.org/10.1111/j.1751-7176.2010.00386.x
28. Malvestutto CD, Aberg JA: HIV and Dyslipidemia. Therapeutic Lipidology. Davidson MH, Toth PP, Maki KC (eds): Springer International Publishing, Cham; 2021. 431-466. 10.1007/978-3-030-56514-5_23
29. Szabo B: Antiandrogenic effect of isotretinoin: Is the retina involved in mechanism of action? Medical Hypotheses. 2007, 69:1281-1283. https://doi.org/10.1016/j.mehy.2007.03.026
30. Eliche Mozas P, Cruz Romero L, Cubillas Quero A, Huertas Escribano MJ, Rus Mansilla C, Cortez Quiroga GA: Consequences of diabetes and high-risk dyslipidemia. European Journal of Preventive Cardiology. 2023, 30:zwad125.161. 10.1093/eurjpc/zwad125.161
31. Prasad K, Mishra M: Mechanism of Hypercholesterolemia-Induced Atherosclerosis. Reviews in Cardiovascular Medicine. 2022, 23:212. 10.31083/j.rcm2306212
32. Wang R, Wang M, Ye J, Sun G, Sun X: Mechanism overview and target mining of atherosclerosis: Endothelial cell injury in atherosclerosis is regulated by glycolysis (Review). Int J Mol Med. 2021, 47:65-76. 10.3892/ijmm.2020.4798
33. Gudas R, Ramchandraiah C, Sanjeev Kumar A: Acute pancreatitis and its association with dyslipidemia. Asian Journal of Medical Sciences. 2022, 13:117-120. 10.3126/ajms.v13i10.47245
34. Anderson F, Thomson SR, Clarke DL, Buccimazza I: Dyslipidaemic Pancreatitis Clinical Assessment and Analysis of Disease Severity and Outcomes. Pancreatology. 2009, 9:252-257. 10.1159/000212091
35. Chalasani N, Younossi Z, Lavine JE, et al.: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-357. 10.1002/hep.29367
36. El Hussein MT, Sharma A, Parmar K, Shelat K: Pharmacotherapeutics for dyslipidemia management. The Nurse Practitioner. 2023, 48.
37. Wiggins BS, Dixon D, Bellone J, Gasbarro N, Marrs JC, Tran R: Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update. Journal of Pharmacy Practice. 2020, 33:882-894. 10.1177/0897190019868413